X

Trial Profile

A study to investigate the coadministration of PTI-801, PTI-808 and PTI-428 in healthy volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Mar 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dirocaftor (Primary) ; Nesolicaftor (Primary) ; Posenacaftor (Primary)
Indications Cystic fibrosis
Focus Adverse reactions

Most Recent Events

14 Mar 2018 According to a Proteostasis Therapeutics media release, based on the data from this trial, triple combination study (see profile 292094 ) protocol received endorsement and a high strategic fit score from the Therapeutics Development Network (TDN) and the Clinical Trial Network (CTN) in January 2018.
15 Dec 2017 New trial record
11 Dec 2017 Results presented in a Proteostasis Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com